Hebei Nengqian Chemical Import and Export Co., LTD
Assessed Supplier Enterprise Certification
- Assessed
Supplier - 4th
years
Assessed Supplier Enterprise Certification
Product Certification&
Enterprise Certification
Country: 
China (Mainland)
Business Type:Trading Company
Tel: +86 18233902561
Mobile: +86 18233902561
Tel: +86 18233902561
Fax: 4001020630
URL: https://www.nengqianchemical.com/
Province/state: Hebei
City: Handan
Street: No.1722, Block C, Yangguang Xinzhuo Plaza, 256 Renmin West Road, Fuxing District, Handan City, Hebei Province
MaxCard:
Ms.AnnaCAS NO.1229236-86-5
medical grade(1-50)Kilogrammedical grade(50-500)Kilogram
Our Advantage
Rich Experience
Our products are sold all over Europe,North&South America, Sino-East, Asia and pacific area as well as Africa,we establish long term.
Quality service
Company cooperates with research institutes. We strictly control the process of raw materials up to finished product.
24 hour service
Quick and clear response to customers questions. Warm after sale service, we will help to solve the problems in your usage.
High quality
Dedicated to serving customers first, we provide reasonable prices, high quality products.
| Molecular Formula | C23H25ClFN7O |
| Molar Mass | 469.94 |
| Density | 1.45 |
| Solubility | DMSO 94 mg/mL (200.02 mM); Water <1 mg/mL (<1 mM); Ethanol 9 mg/mL (19.15 mM) |
| pKa | 14.12±0.10(Predicted) |
| Storage Condition | -20℃ |
| MDL | MFCD20482143 |
| Use | A selective inhibitor of JAK2 mutant V617F. |
| In vitro study | LY2784544 also inhibited IL-3-activated wild-type JAK2 with an IC50 of 2.26 µm. In the proliferation experiment, LY2784544 has anti-proliferative activity with an IC50 of 68 nM in cells driven by JAK2 V617F, while it has an IC50 of 1356 nM in cells driven by wild-type JAK2, when acting on jak3-driven cells, the IC50 was 940 nM. |
| In vivo study | LY2784544 significantly inhibited STAT5 phosphorylation in Ba/F3-JAK2 V617F-GFP xenografts with a threshold effective dose 50 (TED50) of 12.7 mg/kg. LY2784544 acts on the MPN model induced by JAK2 V617F and also reduces the tumor burden V617F-GFP Ba/F3-JAK2, with a TED50 of 13.7 mg/kg after oral treatment. LY2784544 was orally applied to the spleen of SCID mice and had no effect on CD71/Ter119 positive erythroid progenitor cells. |